budesonide MMX (Uceris) vs Budesonide (Uceris rectal foam)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Ulcerative Colitis
Shared mechanism: Glucocorticoid receptor · full Ulcerative Colitis pipeline
budesonide MMX (Uceris)
Marketed by Bausch Health and partners
NCT00679380 · Phase 3 · completed
This was a randomized, fully blinded, placebo-controlled trial of 514 patients with a clinical and endoscopic remission endpoint. The primary comparison was met for the 9 mg dose but not for the 6 mg dose, so the trial gives a split result across the two doses tested.
Reported efficacy
Number of Participants Who Achieved Clinical Remission at Day 56 (Baseline up to Day 56): Registered primary, clinical remission at day 56 (UCDAI rectal bleeding and stool frequency subscores of 0), budesonide MMX 9 mg vs placebo added to oral mesalamine: 56/230 vs 52/228 (CT.gov); similar in both groups, p=0.70 (Rubin 2017). Combined clinical and endoscopic remission at week 8: 13.0% vs 7.5%, p=0.049. (missed)
Result source: NCT01532648
Budesonide (Uceris rectal foam)
Marketed by Bausch Health
NCT01008423 · Phase 3 · completed
The study was a randomized, triple-blind, placebo-controlled trial with 134 participants receiving budesonide and 147 receiving placebo. Its primary endpoint was a clinical-and-endoscopic remission measure, and the comparison significantly favored budesonide at week 6 (44.0% vs 22.4%, p<0.0001).
No aligned efficacy figure on record for this race.
Results for Ulcerative Colitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | budesonide MMX (Uceris) | Budesonide (Uceris rectal foam) |
|---|---|---|
| Clinical remission (induction) | —Not reported | —Not reported |
| Clinical remission (maintenance) | —Not reported | —Not reported |
| Clinical response (induction) | —Not reported | —Not reported |
| Endoscopic improvement (induction) | —Not reported | —Not reported |
| Corticosteroid-free remission (maintenance) | —Not reported | —Not reported |
Clinical remission (induction)
- budesonide MMX (Uceris)
- —Not reported
- Budesonide (Uceris rectal foam)
- —Not reported
Clinical remission (maintenance)
- budesonide MMX (Uceris)
- —Not reported
- Budesonide (Uceris rectal foam)
- —Not reported
Clinical response (induction)
- budesonide MMX (Uceris)
- —Not reported
- Budesonide (Uceris rectal foam)
- —Not reported
Endoscopic improvement (induction)
- budesonide MMX (Uceris)
- —Not reported
- Budesonide (Uceris rectal foam)
- —Not reported
Corticosteroid-free remission (maintenance)
- budesonide MMX (Uceris)
- —Not reported
- Budesonide (Uceris rectal foam)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Budesonide (Uceris rectal foam): registry results are on file for Ulcerative Colitis, but their comparison mappings are not yet available.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: budesonide MMX (Uceris)'s landscape · Budesonide (Uceris rectal foam)'s landscape